New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
16:16 EDTNBIXNeurocrine Biosciences announces VMAT2 inhibitor granted two more patents
Neurocrine Biosciences announced that two additional patents have been granted related to the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor, or VMAT2. European Patent Number 2,081,929 was granted in January 2013 by the European Patent Office with an expiration date of November 2027. The United States Patent and Trademark Office recently granted a second patent. United States Patent Number 8,357,697 covers the method of treating hyperkinetic movement disorders using NBI-98854 and will expire in November 2027.
News For NBIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
16:11 EDTNBIXNeurocrine reports Q2 EPS (28c), consensus (29c)
Subscribe for More Information
July 27, 2015
10:40 EDTNBIXIsis 'most obvious' Biogen takeover target, TheStreet's Feuerstein says
Subscribe for More Information
July 21, 2015
10:01 EDTNBIXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:09 EDTNBIXNeurocrine resumed with an Outperform at Leerink
Leerink resumed shares of Neurocrine with an Outperform rating and $67 price target. The firm says its survey of 51 physicians who treat Tardive dyskinesia and specialist checks on endometriosis support its view that both NBI-98854 and Elagolix could achieve blockbuster status.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use